Lords Mark Industries has commissioned a new 14,000 sq. ft. In Vitro Diagnostics (IVD) manufacturing facility in Maharashtra, ahead of its planned August 2026 timeline. The expansion boosts total footprint to 34,000 sq. ft. and will produce ELISA and rapid test kits.
Lords Mark Industries Expands IVD Manufacturing Capacity
Lords Mark Industries has commissioned a new 14,000 sq. ft. In Vitro Diagnostics (IVD) manufacturing facility in Vasai (East), Maharashtra. The facility is operational two months ahead of its original August 2026 schedule, increasing the company's total manufacturing footprint to 34,000 sq. ft. from 20,000 sq. ft.
Reader Takeaway: Early operational capacity expansion boosts production potential; future R&D focus marks long-term growth strategy.
What just happened
Lords Mark Industries Limited has officially commenced operations at its new In Vitro Diagnostics (IVD) manufacturing unit. This facility adds 14,000 sq. ft. of production space and is now operational, two months prior to its planned August 2026 completion date.
Why this matters
The expansion significantly enhances the company's production capabilities for its portfolio of 56 ELISA test kits and a new range of rapid diagnostic test kits. This increased capacity is crucial for meeting growing demand in the diagnostics market and improving operational efficiency.
The backstory
The company previously operated with a total footprint of 20,000 sq. ft. The strategic decision to expand was driven by the increasing demand in the diagnostics sector and a vision to strengthen indigenous scientific capabilities.
What changes now
With the new facility operational, Lords Mark Industries can scale up the manufacturing of its diagnostic test kits. The R&D division within the facility is dedicated to molecular biology and genetic science research, honouring the Late Shri Ratan Tata.
Risks to watch
Investors should monitor the ramp-up of production utilization at the new facility and the company's ability to translate increased capacity into revenue growth.
Peer comparison
While specific peers are not mentioned in the filing, the diagnostics sector in India is competitive, with companies focusing on expanding manufacturing and R&D capabilities. Lords Mark's early commissioning and focus on specific product lines like ELISA and rapid kits are key differentiators.
Context metrics (time-bound)
The new facility was commissioned in June 2024, ahead of the scheduled August 2026 timeline. A third facility is planned for January 2029.
What to track next
Investors should look for updates on the production output from the new facility and the company's progress on its R&D initiatives, particularly the planned third facility for early cancer detection research by January 2029.